DOI: http://dx.doi.org/10.18203/2320-1770.ijrcog20220888

Four hundred micrograms buccal misoprostol versus five units intravenous oxytocin in prevention of postpartum hemorrhage in elective caesarean section, randomized controlled study

Abo Bakr Abass Mitwally, Abanoub Mansour Tawfik Mansour, Abdel-Ghaffar Mohamed Ahmed

Abstract


Background: The number of studies has been increased about the use of misoprostol during caesarean delivery to prevent obstetric hemorrhage, but may be no study compare buccal misoprostol versus oxytocin in prevention of obstetric hemorrhage during and post cesarean section. Our study is done to compare buccal misoprostol 400 mcg versus oxytocin 5iu intravenous bolus in prevention of postpartum hemorrhage during and post elective cesarean section.

Methods: A prospective registered, double blinded, randomized controlled trial Operative list or emergency unit at Obstetrics and Gynecology Department, Women Health Hospital, Assiut university, Egypt, comparing 77 patients in each group after verbal consent.

Results: There was significant difference between both groups regarding total amount of blood loss (intra partum plus post-partum) 555.45±74.33 in oxytocin group versus522.6±88.76 in misoprostol group.

Conclusions: Buccal misoprostol is more effective than intravenous infusion of oxytocin in reducing blood loss during elective cesarean delivery. However, occurrence of temporary side effects such as fever and chills was more frequent with the use of misoprostol. Clinical trial.gov: NCT03676621.


Keywords


Elective caesarean section, Post-partum haemorrhage, Buccal misoprostol

Full Text:

PDF

References


Betrán AP, Merialdi M, Lauer JA, Bing-Shun W, Thomas J, Van Look P, Wagner M. Rates of caesarean section: analysis of global, regional and national estimates. Paediatr Perinat Epidemiol. 2007;21(2):98-113.

Menacker F, Hamilton BE. (2010): Recent trends in caesarean delivery in the United States. NCHS Data Brief. 2010;(35):1-8.

Mi J, Liu F. Rate of caesarean section is alarming in China. Lancet. 2014;383(9927):1463-4.

Alexander F, Haloob R. Complications of caesarean section Obstetrician and gynecologist. 2016:18:265-72.

Mercier FJ, Van de Velde M. Major obstetric hemorrhage. Anesthesiol Clin. 2008;26(1):53-66.

Mavrides E, Allard S, Chandraharan E, Collins P, Green L, Hunt BJ, et al. Prevention and management of postpartum haemorrhage. BJOG. 2016;124:106-49.

Hernández-Castro F, López-Serna N, Treviño-Salinas EM, Soria-López JA, Sordia-Hernández LH, Cárdenas-Estrada E. Randomized double-blind placebo-controlled trial of buccal misoprostol to reduce the need for additional uterotonic drugs during caesarean delivery. Int J Gynaecol Obstet. 2016;132(2): 184-7.

Bradley SE, Prata N, Young-Lin N, Bishai DM. Cost-effectiveness of misoprostol to control postpartum hemorrhage in low-resource settings. Int J Gynaecol Obstet. 2007;97(1):52-6.

Prata N, Bell S, Weidert K. Prevention of postpartum hemorrhage in low-resource settings: current perspectives. Int J Womens Health. 2013;5:737-52.

Conde-Agudelo A, Nieto A. Rosas-Bermudez A, Romero R. Misoprostol to reduce intraoperative and postoperative hemorrhage during caesarean delivery: a systematic review and metaanalysis. Am J Obstet Gynecol 2013;209(1):40.e1-17.

Abdelaleem AA, Abbas AM, Thabet AL, Badran E, El-Nashar IH. The effect of initiating intravenous oxytocin infusion before uterine incision on the blood loss during elective caesarean section: a randomized clinical trial. J Matern Fetal Neonatal Med. 2019; 32(22):3723-8.

Othman ER, Fayez MF, El Aal DE, El-Dine Mohamed HS, Abbas AM, Ali MK. Sublingual misoprostol versus intravenous oxytocin in reducing bleeding during and after caesarean delivery: A randomized clinical trial. Taiwan J Obstet Gynecol. 2016; 55(6):791-5.

Subedi N, Sharma D, Das R. Comparison of misoprostol with oxytocin in third stage of labour. J Uni Coll Med Sci. 2019;6(1):19-21.

Koch DM, Rattmann YD. Use of misoprostol in the treatment of postpartum hemorrhage: a pharmaco-epidemiological approach. Einstein (Sao Paulo). 2019;18:eAO5029.

Unicef. Trends in maternal mortality: Available at: http//www.tata.unicef.org/resources/trends-maternal-mortality-2000-2017. Accessed on 20 February 2022.

Baskett TF, Persad VL, Clough HJ, Young DC. Misoprostol versus oxytocin for the reduction of postpartum blood loss. Int J Gynaecol Obstet. 2007; 97(1):2-5.

Bellad MB, Tara D, Ganachari MS, Mallapur MD, Goudar SS, Kodkany BS, Sloan NL, Derman R. Prevention of postpartum haemorrhage with sublingual misoprostol or oxytocin: a double-blind randomised controlled trial. BJOG. 2012;119(8):975-82;

Shrestha A, Dongol A, Chawla CD, Adhikari RK. Rectal misoprostol versus intramuscular oxytocin for prevention of post-partum hemorrhage. Kathmandu Univ Med J. 2011;9(33):8-12.

Al-Sawaf A, El-Mazny A, Shohayeb A. A randomised controlled trial of sublingual misoprostol and intramuscular oxytocin for prevention of postpartum haemorrhage. J Obstet Gynaecol. 2013;33(3):277-9.

Atukunda EC, Siedner MJ, Obua C, Mugyenyi GR, Twagirumukiza M, Agaba AG. Sublingual misoprostol versus intramuscular oxytocin for prevention of postpartum hemorrhage in Uganda: a double-blind randomized non-inferiority trial. PLoS Med. 2014; 11(11):e1001752.

Kaudel S, Rana A, Ojha, N. Comparison of oral misoprostol with intramuscular oxytocin in the active management of third stage of labour. Nepal J Obstet Gynaecol. 2013;10(1):76-80.

Nagasree M, Smitha A. Misoprostol versus oxytocin in prevention of postpartum hemorrhage. 2015;5:180-5.

Hamm J., Russell Z., Botha T. Buccal misoprostol to prevent hemorrhage at cesarean delivery: a randomized study. 2005;192:1404-1406.

Tang OS, Gemzell-Danielsson K, Ho PC. Misoprostol: pharmacokinetic profiles, effects on the uterus and side-effects. Int J Gynaecol Obstet. 2007;99(2):S160-7.

Osoti A, Kibii DK, Tong TMK, Maranga I. Effect of extra-amniotic Foley's catheter and vaginal misoprostol versus vaginal misoprostol alone on cervical ripening and induction of labor in Kenya, a randomized controlled trial. BMC Pregnancy Childbirth. 2018;18(1):300.